Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2015

View Archived Issues

JNJ-54861911: promising drug candidate provides stable Abeta reduction

LPCAT-1 implicated in the evolution and progression of breast cancer

Garvan Institute scientists receive support from the Michael J. Fox Foundation

Ocata Therapeutics licenses iPSC technology from Allele Biotechnology

PET imaging of CD4/sr39tk mice enables in vivo tracking of T cells

Novel radiolabeled anti-PSMA nanobody for detection and treatment of prostate cancer

BioLineRx reports topline data for novel stem cell mobilization treatment

Inception 2 patents dual PPARalpha and -delta antagonists

Alexar Therapeutics presents new LXR-beta modulators

NGM Biopharmaceuticals reports phase II data for NGM-282 in primary biliary cirrhosis

Lupin and Indian Rotary Club launch campaign against tuberculosis

Merck & Co. designs small-molecule inhibitors of Hdm2-p53 interaction

Signum Dermalogix licenses SIG-990 to Dermata Therapeutics

Trelagliptin gains first approval in Japan

Daewoong Pharmaceutical presents novel antifungals

Carna Biosciences discloses novel BTK inhibitors

Roche reports development of CB2 receptor agonists

Cladribine receives U.S. orphan drug designation for neuromyelitis optica

Japan Tobacco describes new RORgamma antagonists

European Commission approves Mysimba for weight management

Japanese approval sought for E Keppra as adjunctive therapy for generalized tonic-clonic seizures

Actelion's Opsumit approved in Japan for pulmonary arterial hypertension

MorphoSys regains rights to MOR-202 from Celgene

Aridis starts clinical development of monoclonal antibody against Pseudomonas aeruginosa

Ebola virus vaccines cAd3-EBOZ and VSV-ZEBOV appear to be safe in phase II trial

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...